RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States.
According to the World Health Organization (WHO), acute respiratory infections kill an estimated 3.9 million people per year.
75K to 125K
Each year 75,000 to 125,000 children in this age group are hospitalized due to RSV infection.
Causes of mortality
These infections are one of the top five causes of mortality worldwide.
These infections affect all age groups, but particularly impact the very young, the elderly, and those with chronic medical conditions. In many developing countries, they are the leading killer in children under five years of age.
There is currently no vaccine to protect against RSV infection.
The Agilvax Solution for RSV
Agilvax has recently identified lead RSV vaccine candidates. Characterization of the lead vaccine candidates is currently in progress. Mice immunized with the lead vaccine produced antibodies with neutralization RSV activity. Further in vivo testing is underway.